• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-05-22

  Ramachandran Vijayan et al. employed a structure-based virtual screening of natural products to identify inhibitors of SARS-CoV-2 NSP15, highlighting thymopentin and oleuropein as potent candidates. Their integrative approach advances the rational discovery of antiviral agents targeting viral endoribonucleases and informs future research strategies for COVID-19 therapeutic development.

• ML133 HCl: Precision Potassium Channel Inhibitor for Kir2.1

  2026-05-22

  ML133 HCl stands out as a highly selective potassium channel inhibitor, enabling detailed dissection of Kir2.1 function in vascular remodeling and smooth muscle cell proliferation. This article delivers actionable workflows, troubleshooting strategies, and the latest insights from landmark studies, helping researchers unlock new dimensions in cardiovascular ion channel research.

• Transmission and Plasmid Dynamics of Carbapenemase Genes in

  2026-05-21

  This study provides a detailed characterization of carbapenemase-encoding gene (CEG) prevalence and transmission in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong, China. The findings reveal dominant roles for plasmid-borne blaNDM-1 and high transferability of resistance genes, highlighting urgent challenges for antibiotic resistance research and clinical management.

• Azilsartan Medoxomil: High-Affinity AT1 Blockade in Hyperten

  2026-05-21

  This review details the pharmacological distinctiveness of azilsartan medoxomil (TAK 491), highlighting its high-affinity, long-lasting antagonism of the angiotensin II type 1 receptor in essential hypertension. The findings demonstrate superior blood pressure reduction compared to established ARBs, supporting its value in both mechanistic studies and translational cardiovascular disease research.

• Berberine Hydrochloride: Applied Workflows for Gut-Bone Rese

  2026-05-20

  Berberine hydrochloride enables targeted modulation of the gut-bone axis, offering advanced workflows for both metabolic and osteoimmune research. Explore protocol-driven insights, troubleshooting expertise, and a direct translation of cutting-edge findings into practical lab implementation.

• Dronedarone (Multaq) for Advanced Atrial Fibrillation Resear

  2026-05-20

  Dronedarone (Multaq) from APExBIO delivers a high-purity, robustly soluble, and reproducible platform for atrial fibrillation and flutter research. Leverage improved experimental workflows, cross-validated protocols, and troubleshooting insights to maximize data quality and translational impact in cardiac arrhythmia pharmacology.

• Veratridine: Voltage-Gated Sodium Channel Opener for Researc

  2026-05-19

  Veratridine is a potent voltage-gated sodium channel opener essential for sodium channel dynamics research. Its mechanism, reproducibility, and application range make it a benchmark tool in neuroscience and oncology workflows.

• Verapamil HCl in Bone and Immune Research: Beyond Calcium Bl

  2026-05-19

  Discover how Verapamil HCl, a leading L-type calcium channel blocker, is advancing research into bone metabolism and inflammation. This article reveals new evidence for its mechanistic roles, translational impact, and protocol optimization—going beyond its established uses in myeloma and arthritis models.

• Morin: Protocols and Troubleshooting in Podocyte Injury Mode

  2026-05-18

  Morin, a well-characterized 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, uniquely enables targeted studies of mitochondrial metabolism and podocyte protection in diabetic kidney injury research. This guide translates the latest mechanistic discoveries into actionable workflows and troubleshooting tips, empowering researchers to maximize Morin’s bioactivity and assay reliability.

• Aminopeptidase Inhibitors in Myeloma: Intracellular Mechanis

  2026-05-18

  This study establishes that bestatin and actinonin, both aminopeptidase inhibitors, suppress myeloma cell proliferation primarily through intracellular interactions rather than cell surface enzyme inhibition. The findings clarify drug resistance mechanisms and highlight the role of drug efflux transporters, offering methodological guidance for apoptosis and drug synergy research in myeloma.

• Isradipine (Dynacirc): Mechanistic Leverage for Translationa

  2026-05-17

  This article provides translational researchers with a mechanistic, evidence-backed framework for deploying Isradipine (Dynacirc) in studies of neuroprotection and vascular biology. Building on foundational pharmacology and recent advances in calcium channel classification, we present strategic guidance for experimental design and highlight the product quality differentiators offered by APExBIO. The discussion integrates primary literature, comparative insights, and actionable protocols, setting a new standard for scientific rigor and translational relevance.

• BAPTA-AM: Precision Calcium Modulation for NMJ Synapse Resea

  2026-05-16

  This article provides translational researchers with mechanistic insight and strategic guidance on leveraging BAPTA-AM—a cell-permeable calcium chelator—from APExBIO to dissect spatially regulated, calcium-dependent BDNF signaling during neuromuscular junction (NMJ) development. Drawing on recent advances in live-cell imaging and molecular targeting, the discussion synthesizes protocol parameters, competitive benchmarks, and translational implications, while bridging the gap between traditional product information and forward-looking neurobiological assay design.

• Meta-Analysis: Efficacy and Safety of Azilsartan Medoxomil i

  2026-05-15

  This systematic review and meta-analysis synthesizes evidence from 11 randomized controlled trials, assessing azilsartan medoxomil (TAK 491) for blood pressure reduction in hypertensive patients, including those with diabetes. The study demonstrates superior antihypertensive efficacy compared to control therapies without increasing adverse event risk, providing robust, clinically relevant insights for essential hypertension treatment research.

• Hypoxia-Preconditioned hBMSCs Enhance Mitochondrial Transfer

  2026-05-15

  Luo et al. (2025) reveal that hypoxia-preconditioning of human bone marrow-derived mesenchymal stem cells (hBMSCs) boosts their ability to transfer high-quality mitochondria to hepatocytes via connexin 43 (Cx43) and connexin 32 (Cx32) gap junctions, alleviating ischemia-reperfusion injury (IRI) in liver grafts. The study highlights the essential role of gap junction modulation—specifically using peptide inhibitors like Gap26—in dissecting intercellular mitochondrial signaling and offers a rigorous model for future translational research.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Model

  2026-05-14

  This article examines the discovery of new allosteric inhibitors targeting pyruvate dehydrogenase kinase 4 (PDK4), focusing on compound 8c, which demonstrated high potency, metabolic stability, and efficacy in models of metabolic, allergic, and oncological diseases. The findings provide a validated scaffold for further drug development in metabolic disease therapy.

3720 records 20/248 page Previous Next First page 上5页 1617181920 下5页 Last page